ORPHA:169808
Mild hemophilia A
Also known as: Mild congenital F8 deficiency · Mild congenital factor VIII deficiency
Publications
1,219
Trials
3
Interventional, condition-specific
Researchers
1,151
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A mild form of hemophilia A characterized by a small deficiency of factor VIII (biological activity between 5 and 40 IU/dL) leading to abnormal bleeding as a result of minor injuries or following surgery or tooth extraction. Spontaneous hemorrhages do not occur. Patients may be also labeled as having mild hemophilia A if they have a FVIII >40 IU/dL and a DNA change in the F8 gene and one of the following: (i) a family member with the same DNA change and FVIII of <40 IU/dL, and the DNA change is found in <1% of the population; and (ii) the international databases list the DNA change as being associated with hemophilia A and <40 IU/dL FVIII. The condition may affect males and female carriers of disease-causing mutations.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0015721
- UMLS:C0272324
Additional Mondo synonyms (3)
mild factor VIII deficiency · mild haemophilia type A · mild hemophilia type A
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,219 matched papers (704 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
3 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
1,219
1,219 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
1,219 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
704 in the last 10 years · low confidence
Phrase hits: 1,219 · MeSH hits: 0
Who's working on it?
1,151
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Fijnvandraat K10 papers · 2025
Pediatric Hematology Amsterdam UMC Emma Children's Hospital University of Amsterdam Amsterdam The Netherlands.
Papers in Europe PMC - 02Coppens M9 papers · 2025
Department of Vascular Medicine, Amsterdam University Medical Centres, Amsterdam, the Netherlands.
Papers in Europe PMC - 03Leebeek FWG9 papers · 2025
Department of Hematology, Erasmus MC, Rotterdam, the Netherlands.
Papers in Europe PMC - 04Castaman G8 papers · 2025
Department of Oncology Center for Bleeding Disorders Careggi University Hospital Florence Italy.
Papers in Europe PMC - 05Gouw SC7 papers · 2023
Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.
Papers in Europe PMC - 06Pabinger I7 papers · 2025
Clinical Division of Hematology and Hemastaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Papers in Europe PMC - 07Hermans C6 papers · 2026
Hemostasis and Thrombosis Unit, Division of Hematology, Cliniques Universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), 1200 Brussels, Belgium. Electronic address: cedric.hermans@uclouvain.be.
Papers in Europe PMC - 08Nogami K6 papers · 2026
Department of Pediatrics, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan.
Papers in Europe PMC - 09Peyvandi F6 papers · 2026
Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.
Papers in Europe PMC - 10Beckers EAM5 papers · 2023
Department of Hematology, Maastricht University Medical Centre, Maastricht, the Netherlands.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
3
interventional trials for this specific condition
3 interventional trials matched this specific condition name; 1 currently recruiting in our sample. 332 trials are registered for hemophilia A, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
3 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 85.1th percentile).
low confidence · 85.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
3 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT04567511·RECRUITING·Hemlibra in Mild Hemophilia A
Conditions: Factor VIII Deficiency, Congenital·Matched via name phrase
Broader category: hemophilia A
332
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06816056·RECRUITING·Manual Therapy in Hemophilic Arthropathy of the Ankle
Conditions: Hemophilia A·Matched via name phrase
- NCT06145373·RECRUITING·A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
Conditions: Hemophilia A·Matched via name phrase
- NCT05611801·RECRUITING·A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
Conditions: Hemophilia A · Hemophilia B·Matched via name phrase
- NCT05145127·RECRUITING·Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Conditions: Hemophilia A · Hemophilia B·Matched via name phrase
- NCT07421154·NOT YET RECRUITING·Study of a Smart Sharps Disposal Device in Patients With Hemophilia
Conditions: Hemophilia A and B·Matched via name phrase
- NCT07545395·RECRUITING·Safety of KN057 Prophylaxis in Patients With Haemophilia A or B
Conditions: Hemophilia A or B·Matched via name phrase
- NCT07200609·NOT YET RECRUITING·The Effects of Virtual Reality-Based Gamified Rehabilitation in Children With Hemophilia
Conditions: Hemophilia A Without Inhibitor·Matched via name phrase
- NCT03217032·RECRUITING·Lentiviral FVIII Gene Therapy
Conditions: Hemophilia A·Matched via name phrase
- NCT07416526·RECRUITING·A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
Conditions: Hemophilia A·Matched via name phrase
- NCT07285460·RECRUITING·A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
Conditions: Hemophilia·Matched via name phrase
- NCT07226206·RECRUITING·A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
Conditions: Hemophilia A·Matched via name phrase
- NCT06864975·RECRUITING·Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)
Conditions: Hemophilia a with Inhibitor·Matched via name phrase
- NCT04728841·RECRUITING·Gene Therapy for Chinese Hemophilia A
Conditions: Hemophilia A · Gene Therapy·Matched via name phrase
- NCT06320626·RECRUITING·Pharmacokinetic-guided Dosing of Emicizumab
Conditions: Hemophilia A With Inhibitor · Hemophilia A Without Inhibitor · Hemophilia A, Severe · Adolescent·Matched via name phrase
- NCT06938659·NOT YET RECRUITING·Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A Patients
Conditions: Hemophilia A·Matched via name phrase
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Mild hemophilia A" OR "Mild congenital F8 deficiency" OR "Mild congenital factor VIII deficiency" OR "mild factor VIII deficiency" OR "mild haemophilia type A" OR "mild hemophilia type A"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Mild hemophilia A" OR "Mild congenital F8 deficiency" OR "Mild congenital factor VIII deficiency" OR "mild factor VIII deficiency" OR "mild haemophilia type A" OR "mild hemophilia type A"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 3 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"hemophilia A"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1219) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T08:38:36.957Z
